Skip to content
- 2020 Q4
– Darmiyan presented validation results in CTAD 2020 - 2020 Q2 & Q3
– Darmiyan CEO was selected by Fortune 40 under 40
– Darmiyan’s core technology, BrainSee, was blind-tested and validated by independent third-party investigators in the US and Canada. See press release here. - 2020 Q1
– Pharma giant Eisai led a $6M round in Darmiyan
– US patent was published - 2019 Q4
– Blind testing validation results are published in BioRxiv, and established ~ 90% accuracy in the diagnosis of MCI and AD and 5-year prognosis of MCI
– Started POC study with Banner Alzheimer’s Institute, focused on early detection of AD at preclinical (presymptomatic) stage
– Presented at CTAD (Clinical Trials on Alzheimer’s Disease) 2019 conference, San Diego
– Presented at Washington Longevity Summit, Washington DC
– Press room in Washington DC - 2019 Q3
– Released BrainSee version 1.0
– Tested the product on 3170 brain scans (Normal, MCI, AD) and 411 longitudinal MCI cases with 5-year follow up
– Signed partnership with Mary Furlong & Associates
– Podcast with Dr. Allison Sekuler, Mary Furlong and Darmiyan CTO Dr. Kaveh Vejdani recorded in UC Berkeley
– Patents filed in Europe and Asia - 2019 Q2
– Developed a fully automated pipeline for image processing and data analysis
– Featured article, Alzheimer’s disease noise or signal, in response to Bill Gates - 2019 Q1
– Met with FDA in Washington to discuss regulatory strategy
– Partnership signed with CABHI (Center for Aging and Brain Health Innovation) partner sites Baycrest Institute, University Health Network (UHN) and Hamilton Health Sciences
– Presented at CABHI’s What’s Next Canada meeting in Toronto and won the 2019 CABHI Innovation Award
– Toronto office was opened to explore business development opportunities in Canada - 2018 Q4
– Presented at TEDMED Hive, Palm Springs, CA
– FDA Q-sub (pre-submission) application sent - 2018 Q3
– Panelist at MedTech Conference, Neurotechnology section, Philadelphia, PA
– Moved to a new office space in downtown San Francisco, CA - 2018 Q2
– Won a CABHI Industry Innovation (I2P2) award for CAN $500K
– PCT patents filed and US patent application was fast-tracked
– Signed partnership agreement with Boston University - 2018 Q1
– Image analysis and machine learning pipelines designed and developed
– Signed partnership agreement with Banner Alzheimer’s Institute - 2017 Q4
– Graduated from SkyDeck UC Berkeley
– Moved to new office space in Emeryville, CA, team expanded to 6 FTE
– Non-provisional US patent filed - 2017 Q3
– Graduated from Y-Combinator program
– Raised seed financing
– VentureBeat news published
– Hacker News article released
– WSGR engaged as IP legal counsel - 2017 Q2
– Won Amgen-QB3/MBC Biolabs Golden Ticket Award
– Accepted to Y-Combinator S17 Batch
– Accepted to SkyDeck UC Berkeley - 2017 Q1
– Product designed and strategy identified
– Prototype developed and got preliminary results - 2016
– Paul Hastings LLP engaged as legal counsel
– Incorporated in Delaware
– Registered in California and raised pre-seed financing - 2015
– Completed the feasibility studies and model validation by microscopy
– Member company of Harlem Biospace, New York - 2014
– Developed the core technology and product concept
– Successfully completed New York regional NSF I-Corps program